Catherine Longworth

London

Healthcare Editor & Journalist @Healthcare_GD Tweeting about #Healthcare #Medtech #DigitalHealth Views my own Contact me: [email protected]

Featured in: Favicon

medicaldevice-network.com Favicon

informa.com (+1) Favicon

pharmaphorum.com Favicon

yourlocalguardian.co.uk Favicon

clinicaltrialsarena.com Favicon

bioworld.com Favicon

surreycomet.co.uk Favicon

wimbledonguardian.co.uk Favicon

wandsworthguardian.co.uk Favicon

kingstonguardian.co.uk + 3 more

Articles

3D printing medical devices: industry unlocks new possibilities

1 month ago | medicaldevice-network.com | Catherine Longworth

As momentum continues to build, medical device companies are ramping up their investment in 3D printing technology. Driven by a strong focus on innovation and improving patient outcomes, the adoption of 3D printing services is rapidly expanding across the sector. According to GlobalData analysis, the medical 3D printing market is set to grow from a $2bn market in 2022 to $4bn in 2026 at a compound annual growth rate (CAGR) of 21%.
Features - Medical Device Network

Dec 2, 2024 | medicaldevice-network.com | Robert Barrie |Catherine Longworth |Jenna Philpott |Joshua Silverwood

Skip to site menuSkip to page content What’s next in prostate cancer detection technologies? With seven Olympic medals to his name – six of which are gold – Chris Hoy is one of the…
FDA LDT litigation could be ‘train wreck in the courts’

Oct 17, 2024 | finance.yahoo.com | Catherine Longworth

Litigation against the FDA's Final Rule on lab-developed tests (LDTs) is causing uncertainty to rise as the US regulator gears up for a legal clash with the lab industry. Since the FDA revealed its controversial Final Rule on LDTs, two laboratory associations have filed lawsuits which are now pending in one consolidated case in the U.S District Court for the Eastern District of Texas.
FDA LDT litigation could be 'train wreck in the courts'

Oct 17, 2024 | medicaldevice-network.com | Catherine Longworth
China Plus One? MedTech’s search for adaptable supply chain models

Oct 16, 2024 | finance.yahoo.com | Catherine Longworth

Device companies are establishing manufacturing operations outside of China to reduce dependence on Chinese manufacturing, but setting up facilities in "Plus One" countries is not without it's hurdles. During a panel discussion at AdvaMed’s The MedTech Conference in Toronto, supply chain leaders highlighted the risks and benefits of so called China Plus One (C+1) strategies.
Mobidiag Launches Automobi Joint Venture In China

Oct 15, 2024 | insights.citeline.com | Catherine Longworth

Mobidiag Launches Automobi Joint Venture In China03 Jun 2019 • By Catherine LongworthFinnish diagnostics company Mobidiag has launched its new joint venture with partner Autobio Diagnostics called Automobi.
ADA 2020: Abbott Expects CGM To Reduce Insulin Needed For Type 2 Diabetes

Oct 15, 2024 | insights.citeline.com | Catherine Longworth

ADA 2020: Abbott Expects CGM To Reduce Insulin Needed For Type 2 Diabetes19 Jun 2020 • By Catherine LongworthResearch presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.
Harnessing LLMs in clinical trial management

Sep 30, 2024 | clinicaltrialsarena.com | Catherine Longworth

The use of large language models (LLMs) such as ChatGPT will be key in enhancing clinical trial management according to Endpoint Clinical’s Senior Director of Solutions Consulting, Chris Varner. During a presentation at the 17th Annual Clinical Trial Supply West Coast 2024 conference in San Francisco, Varner, discussed how tools such as ChatGPT are transforming the landscape of Interactive Response Technology (IRT).
Genolier Health Innovation Hub opens in Switzerland

Sep 30, 2024 | medicaldevice-network.com | Catherine Longworth

A new health innovation hub has launched in Switzerland, with the aim of accelerating late stage medical research into clinic. Located in Switzerland’s Health Valley, the Genolier Innovation Hub is designed to bring late-stage medtech, pharma, biotech, and digital health companies together to speed innovation to market. The research centre is the brainchild of Swiss investment group Aevis Victoria SA, who have injected more than CHF 100 million ($118 million) into its development.
“Leave politics out of healthcare” - controversy swirls around BIOSECURE Act

Sep 18, 2024 | clinicaltrialsarena.com | Catherine Longworth

Members of the biotech industry have voiced concerns about the impact of the BIOSECURE Act, after the bill passed through the U.S. House of Representatives last week. During a panel discussion on supply chain challenges at the Clinical Trial Supply West Coast 2024 conference in San Francisco, Umar Hayat, Chief Technology Officer of US company Gladius Therapeutics, led criticism of the bill and said politics needed to stay out of the healthcare industry.